Health-care companies rose after strong earnings from one drug giant.
Bristol-Myers Squibb's net profit rose slightly in the third quarter on strong sales of a blood thinner, which offset lower sales of a key oncology drug.
The Food and Drug Administration postponed a planned joint meeting of two of its advisory committees to review Perrigo's commercialization application for the Opill birth-control drug.
ESSA Pharma shares more than doubled after its lead drug candidate EPI-7386 showed promise in a prostate cancer study.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
10-26-22 1714ET
